Valuation: Exelixis, Inc.

Market Cap 13.64B 11.95B 11.03B 10.3B 19.39B 1,290B 19.83B 133B 51.23B 636B 51.24B 50.11B 2,209B P/E 2026 *
17.1x
P/E 2027 * 14.7x
Enterprise Value 12.87B 11.27B 10.41B 9.72B 18.29B 1,217B 18.71B 125B 48.34B 600B 48.35B 47.28B 2,085B EV / Sales 2026 *
4.95x
EV / Sales 2027 * 4.08x
Free-Float
98.18%
Yield 2026 *
-
Yield 2027 * -
1 day-0.89%
1 week+5.71%
Current month+7.53%
1 month+7.53%
3 months+30.70%
6 months+19.64%
Current year+23.84%
1 week 51.7
Extreme 51.7
55.91
1 month 48.1
Extreme 48.1036
55.91
Current year 39.71
Extreme 39.71
55.91
1 year 33.76
Extreme 33.755
55.91
3 years 18.64
Extreme 18.64
55.91
5 years 14.87
Extreme 14.87
55.91
10 years 7.81
Extreme 7.81
55.91
Manager TitleAgeSince
Chief Executive Officer 65 22/07/2010
Director of Finance/CFO 58 15/07/2015
Chief Operating Officer 63 01/02/2016
Director TitleAgeSince
Director/Board Member 70 01/02/2004
Director/Board Member 82 01/08/2004
Chairman 77 01/01/1998
Date Insider Type Main position Quantity % Market Cap.
01/06Sell

Director

-9,812 0.0039%
01/06Sell

Director

-3,925 0.0016%
27/05Free

Director

8,367 0.0033%
Change 5-day change 1-year change 3-year change Capi.($)
-0.89%+5.71%+24.30%+186.29% 13.64B
+2.78%-0.62%+71.99%+127.35% 55.78B
+6.76%+18.10%+91.66%+104.09% 55.66B
+3.33%+4.51%-11.68%-11.91% 23.84B
+1.32%+6.22%+5.28%+415.45% 22.7B
+6.53%+7.17%+39.24%-29.03% 16.12B
+9.96%+15.98%+157.65%+310.89% 14.8B
+2.85%+2.81%+75.32%+139.44% 12.16B
+6.17%+10.22%+163.15%+166.44% 11.85B
+2.04%-1.83%+400.62%+124.05% 11.34B
Average +4.09%+6.48%+101.75%+153.31% 23.79B
Weighted average by Cap. +4.28%+7.25%+82.59%+142.05%

Financials

2026 *2027 *
Net sales 2.6B 2.28B 2.1B 1.96B 3.69B 246B 3.78B 25.29B 9.76B 121B 9.76B 9.55B 421B 2.92B 2.56B 2.36B 2.21B 4.15B 276B 4.25B 28.43B 10.97B 136B 10.97B 10.73B 473B
Net income 818M 716M 661M 618M 1.16B 77.36B 1.19B 7.96B 3.07B 38.16B 3.07B 3.01B 133B 934M 818M 755M 705M 1.33B 88.33B 1.36B 9.09B 3.51B 43.58B 3.51B 3.43B 151B
Net Debt -770M -674M -622M -581M -1.09B -72.8B -1.12B -7.49B -2.89B -35.92B -2.89B -2.83B -125B -1.73B -1.52B -1.4B -1.31B -2.46B -164B -2.52B -16.84B -6.5B -80.74B -6.5B -6.36B -280B
Logo Exelixis, Inc.
Exelixis, Inc. is an oncology company. The Company has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. It is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.
Employees
1,077
Date Price Change Volume
29/06/26 USD 54.28 -0.89% 2,587,750
26/06/26 USD 54.77 +2.89% 6,931,468
25/06/26 USD 53.23 +0.68% 2,256,253
24/06/26 USD 52.87 +2.98% 2,931,626
23/06/26 USD 51.34 -0.02% 2,574,378
Trader
Investor
Global
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
54.28USD
Average target price
49.50USD
Spread / Average Target
-8.81%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. EXEL Stock